Review



poly i c hmw vaccigradetm  (InvivoGen)


Bioz Verified Symbol InvivoGen is a verified supplier
Bioz Manufacturer Symbol InvivoGen manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    InvivoGen poly i c hmw vaccigradetm
    Poly I C Hmw Vaccigradetm, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 181 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/bio_rxiv__64898__2026__05__13__724871-146-0-6
    Average 96 stars, based on 181 article reviews
    poly i c hmw vaccigradetm - by Bioz Stars, 2026-09
    96/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
    Article Snippet: .. Each Nature Communications | (2023) 14:7056 12 injection contained 25μg of individual peptide +25μg of Poly(I:C) (HMW) VacciGrade (Invivogen; San Diego, CA), to a final injection volumeof 50μl. ..

    Article Title: Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
    Article Snippet: .. Each injection contained 25 μg of individual peptide +25 μg of Poly(I:C) (HMW) VacciGrade (Invivogen; San Diego, CA), to a final injection volume of 50 μl. ..

    Article Title: SARS-CoV-2 infection elucidates unique features of pregnancy-specific immunity
    Article Snippet: IL-27 levels were monitored with an ELISA kit (R&D systems). .. To induce fetal demise in pregnant mice, E12.5 pregnant mice were injected with 600 μg poly(I:C) (HMW) VacciGrade (InvivoGen). ..

    Adjuvant:

    Article Title: Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses
    Article Snippet: CpG ODN 2395 (5′-TCGTCGTTTTCGGCGCGCGCCG-3′) was obtained from Integrated DNA Technologies (IDT, Coralville, IA, USA). .. Poly(I:C)-HMW VacciGrade and Incomplete Freund’s Adjuvant (IFA) were purchased from InvivoGen (San Diego, CA, USA). .. GM-CSF was purchased from PeproTech (Rocky Hill, NJ, USA).

    Immunofluorescence:

    Article Title: Lipid nanoparticle encapsulated TLR3 agonist adjuvant elicits potent T cell immunity against cancer and viruses
    Article Snippet: CpG ODN 2395 (5′-TCGTCGTTTTCGGCGCGCGCCG-3′) was obtained from Integrated DNA Technologies (IDT, Coralville, IA, USA). .. Poly(I:C)-HMW VacciGrade and Incomplete Freund’s Adjuvant (IFA) were purchased from InvivoGen (San Diego, CA, USA). .. GM-CSF was purchased from PeproTech (Rocky Hill, NJ, USA).

    In Vivo:

    Article Title: Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
    Article Snippet: .. For the assessment of efficacy of our selected immunogenic peptides to impact the engraftment and progression of AB12 murine mesothelioma cell line in vivo, we preimmunized a cohort of Balb/cOlaHsd mice with either PBS (Mock), Poly(I:C) (HMW) VacciGrade (Invivogen; San Diego, CA) (polyIC) or Poly(I:C) together with peptides 11 and 12 (poly IC + peptides). ..

    Article Title: Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.
    Article Snippet: .. For the assessment of efficacy of our selected immunogenic peptides to impact the engraftment and progression of AB12 murine mesothelioma cell line in vivo, we preimmunized a cohort of Balb/ cOlaHsd mice with either PBS (Mock), Poly(I:C) (HMW) VacciGrade (Invivogen; SanDiego, CA) (polyIC) or Poly(I:C) together with peptides 11 and 12 (poly IC + peptides). ..



    Similar Products

    poly i c hmw vaccigradetm  (InvivoGen)
    96
    InvivoGen poly i c hmw vaccigradetm
    Poly I C Hmw Vaccigradetm, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/bio_rxiv__64898__2026__05__13__724871-146-0-6
    Average 96 stars, based on 1 article reviews
    poly i c hmw vaccigradetm - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    i c pic  (InvivoGen)
    96
    InvivoGen i c pic
    I C Pic, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/pm41974867-220-12-15
    Average 96 stars, based on 1 article reviews
    i c pic - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    tlr3 ligand  (InvivoGen)
    96
    InvivoGen tlr3 ligand
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    Tlr3 Ligand, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/pmc13148951-215-10-14
    Average 96 stars, based on 1 article reviews
    tlr3 ligand - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    i c  (InvivoGen)
    96
    InvivoGen i c
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    I C, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/pmc12909587-95-12-13
    Average 96 stars, based on 1 article reviews
    i c - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    polyic  (InvivoGen)
    96
    InvivoGen polyic
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    Polyic, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/us12539310-285-0-1
    Average 96 stars, based on 1 article reviews
    polyic - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    polyinosinic polycytidylic acid  (InvivoGen)
    96
    InvivoGen polyinosinic polycytidylic acid
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    Polyinosinic Polycytidylic Acid, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/10__1172_slash_jci195784-192-44-48
    Average 96 stars, based on 1 article reviews
    polyinosinic polycytidylic acid - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    hmw vaccigradetm  (InvivoGen)
    96
    InvivoGen hmw vaccigradetm
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    Hmw Vaccigradetm, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/us12514919-278-3-1
    Average 96 stars, based on 1 article reviews
    hmw vaccigradetm - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    vac pic  (InvivoGen)
    96
    InvivoGen vac pic
    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists <t>(TLR3,</t> TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.
    Vac Pic, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/poly(i%3Ac)+(hmw)+vaccigrade/Poly(I%3AC)+(HMW)+VacciGrade/us12514919-278-7-1
    Average 96 stars, based on 1 article reviews
    vac pic - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists (TLR3, TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.

    Journal: Molecular Therapy Advances

    Article Title: Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release

    doi: 10.1016/j.omta.2026.201698

    Figure Lengend Snippet: In vivo or in vitro treatment with pDNA-LNP increased IFN-I release (A) Mice were treated as in B with PBS or 30μg of mRNA-LNP, pDNA, or pDNA-LNP. Sera were collected on day 12 and assessed for IFN-β concentration by ELISA. (B) Splenocytes from wild-type mice were incubated with media alone, a pool of Toll-like receptor agonists (TLR3, TLR7, and TLR9 agonists as positive control), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. (C) Splenocytes from wild-type mice were incubated with media alone or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed by Luminex for CXCL10 and CCL7. (A and B) N = 3 mice per group. (C) Data are technical replicates from one mouse per group. ∗ p < 0.05 and ∗∗ p < 0.01 as assessed by one-way ANOVA with Tukey’s correction for multiple comparisons. Error bars represent mean ± SD. Experiment in (B and C) is representative of one other independent experiment.

    Article Snippet: In some cases, cells were also incubated with 10 μg/mL TLR3 ligand (poly I:C, InVivoGen #vac-pic, San Diego, CA), 3 μg/mL TLR7 ligand (Gardiquimod, InVivoGen #tlrl-gdqs-1), 5 μM TLR9 ligand (ODN1826, Integrated DNA Technologies, San Diego, CA), 0.5 μM STING agonist (diABZI, InVivoGen #tlrl-diabzi-2; a generous gift from Dr.

    Techniques: In Vivo, In Vitro, Concentration Assay, Enzyme-linked Immunosorbent Assay, Incubation, Positive Control, Luminex

    Increased IFN-β levels were not due to TLR3, 7, or 9 signaling but were at least partially mediated by STING signaling (A) Splenocytes from wild-type, TLR3 knockout (TLR3KO), TLR7KO, or TLR9KO were incubated with indicated TLR ligands or 1 μg per well of mRNA-LNP, mRNA, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice per strain. (B) Splenocytes from wild-type or STING knockout mice were incubated with a pool of TLR ligands, diABZI (STING agonist), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice/strain. Supernatants were assessed for IFN-β (by ELISA), or CXCL10, CCL7, or CCL5 (by Luminex). N = 3 mice per strain (ELISA) or N = 1 mouse per strain assessed in technical replicates (Luminex studies). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 as assessed by one-way ANOVA with Tukey’s correction for multiple comparison. Results are from one experiment (A, and Luminex studies in B) or are representative of two independent experiments (IFN-β ELISA).

    Journal: Molecular Therapy Advances

    Article Title: Plasmid DNA vaccines encapsulated in lipid nanoparticles elicit STING-dependent type 1 interferon release

    doi: 10.1016/j.omta.2026.201698

    Figure Lengend Snippet: Increased IFN-β levels were not due to TLR3, 7, or 9 signaling but were at least partially mediated by STING signaling (A) Splenocytes from wild-type, TLR3 knockout (TLR3KO), TLR7KO, or TLR9KO were incubated with indicated TLR ligands or 1 μg per well of mRNA-LNP, mRNA, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice per strain. (B) Splenocytes from wild-type or STING knockout mice were incubated with a pool of TLR ligands, diABZI (STING agonist), or 1 μg per well of mRNA, mRNA-LNP, pDNA, or pDNA-LNP for 48 h. Supernatants were assessed for IFN-β by ELISA. N = 3 mice/strain. Supernatants were assessed for IFN-β (by ELISA), or CXCL10, CCL7, or CCL5 (by Luminex). N = 3 mice per strain (ELISA) or N = 1 mouse per strain assessed in technical replicates (Luminex studies). ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001 as assessed by one-way ANOVA with Tukey’s correction for multiple comparison. Results are from one experiment (A, and Luminex studies in B) or are representative of two independent experiments (IFN-β ELISA).

    Article Snippet: In some cases, cells were also incubated with 10 μg/mL TLR3 ligand (poly I:C, InVivoGen #vac-pic, San Diego, CA), 3 μg/mL TLR7 ligand (Gardiquimod, InVivoGen #tlrl-gdqs-1), 5 μM TLR9 ligand (ODN1826, Integrated DNA Technologies, San Diego, CA), 0.5 μM STING agonist (diABZI, InVivoGen #tlrl-diabzi-2; a generous gift from Dr.

    Techniques: Knock-Out, Incubation, Enzyme-linked Immunosorbent Assay, Luminex, Comparison